Severe adverse events during sirolimus "off-label" therapy for vascular anomalies.
Rössler J, Baselga E, Davila V, Celis V, Diociaiuti A, El Hachem M, Mestre S, Haeberli D, Prokop A, Hanke C, Loichinger W, Quéré I, Baumgartner I, Niemeyer CM, Kapp FG.
Rössler J, et al. Among authors: baumgartner i.
Pediatr Blood Cancer. 2021 Aug;68(8):e28936. doi: 10.1002/pbc.28936. Epub 2021 Feb 13.
Pediatr Blood Cancer. 2021.
PMID: 33580918